285) enib before radiation therapy and similar tumor shrinkage occurred within 16 days. |
286) se of vemurafenib resulted in significant tumor shrinkage that allowed for the compl |
287) combination treatment markedly decreased tumor size, but only DFMO increased surviv |
288) ased host immune response acted to reduce tumor size, suggesting that increasing MPO |
289) We assessed the mean tumor size, ulcer diameter, exposed blood |
290) classification, lymph node metastasis and Tumor-Node-Metastasis stage. |
291) pends on histological differentiation and tumor stage. |
292) f PG for GEJ adenocarcinoma regardless of tumor stage. |
293) sion in urothelial carcinomas or in other tumor types including lung adenocarcinoma, |
294) gene for breast carcinoma across 31 solid tumor types. |
295) igated molecular changes in the different tumor types. |
296) triclabendazole significantly reduced the tumor volume by promoting the cleavage of |
297) odel, CD40L-MTV-NPs significantly reduced tumor volume in correlation with significa |
298) Therapeutic efficacy was assessed by tumor volume measurements (CT), time to pr |
299) mother-daughter pair, a somatic cause of tumor MMR deficiency was supported by the |
300) fidently assigned a noninherited cause of tumor MMR deficiency. |
301) isorders related to the vertebrae, spinal tumor ablation, vertebral augmentation, an |
302) ave been widely studied, including spinal tumor ablation, vertebral augmentation, an |
303) agonist 2'3'-cGAMP, TLR9 ligand CpG, and tumor antigen peptides that are loaded int |
304) ugates (ADCs) combine the highly targeted tumor antigen recognition of antibodies wi |
305) CD4+T cells from non-tumor bearing mice were isolated from sple |
306) rom draining lymph nodes and spleens from tumor bearing C57Bl/6 mice, 28 days post-i |
307) s the sensitivity of radiomic features to tumor boundaries. |
308) ified sensitivity of radiomic features to tumor boundaries. |
309) overcame insufficient immunity at distant tumor caused by PTT alone and relieved imm |
310) ercoming insufficient immunity at distant tumor caused by PTT alone. |
311) sessed and optimized in order to maximize tumor-absorbed dose while keeping normal o |
312) Such imaging may be used to estimate tumor-absorbed dose. |
313) ws the research results on organoids from tumor drug screening. |
314) ir applications in cancer therapy include tumor-targeting drug delivery and controll |
315) and anti-PD-1 cotreatment may enhance antitumor effects consistent with an increase |
316) ide the first line of defense against the tumor-promoting effects of oxidative stres |
317) D20 CAR T cells demonstrate improved anti-tumor efficacy in response to dual antigen |
|